These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24973646)

  • 1. Safety information on QT-interval prolongation: comparison of European Union and United States drug labeling.
    Warnier MJ; Holtkamp FA; Rutten FH; Hoes AW; de Boer A; Mol PG; De Bruin ML
    Drug Discov Today; 2014 Sep; 19(9):1294-7. PubMed ID: 24973646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of drug label information on QT interval prolongation.
    Warnier MJ; Holtkamp FA; Rutten FH; Hoes AW; de Boer A; Mol PG; De Bruin ML
    Int J Risk Saf Med; 2014; 26(2):89-98. PubMed ID: 24902506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of drug-related QT prolongation on FDA regulatory decisions.
    Park E; Willard J; Bi D; Fiszman M; Kozeli D; Koerner J
    Int J Cardiol; 2013 Oct; 168(5):4975-6. PubMed ID: 23920061
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prolongation of QT interval and evaluation of safety of drugs].
    Li Y; Xu J; Zhang W
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Aug; 30(4):905-8. PubMed ID: 24059079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram.
    Pae CU; Wang SM; Lee SJ; Han C; Patkar AA; Masand PS
    Expert Opin Drug Saf; 2014 Feb; 13(2):197-205. PubMed ID: 24131458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
    Gintant G
    Pharmacol Ther; 2011 Feb; 129(2):109-19. PubMed ID: 20807552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preclinical assessment of the risk for QT interval prolongation.
    Champeroux P; Martel E; Vannier C; Blanc V; Leguennec JY; Fowler J; Richard S
    Therapie; 2000; 55(1):101-9. PubMed ID: 10860008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study.
    Iribarren C; Round AD; Peng JA; Lu M; Zaroff JG; Holve TJ; Prasad A; Stang P
    Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1222-32. PubMed ID: 23857878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Droperidol, QT prolongation, and sudden death: what is the evidence?
    Kao LW; Kirk MA; Evers SJ; Rosenfeld SH
    Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries.
    De Ponti F; Poluzzi E; Vaccheri A; Bergman U; Bjerrum L; Ferguson J; Frenz KJ; McManus P; Schubert I; Selke G; Terzis-Vaslamatzis G; Montanaro N
    Br J Clin Pharmacol; 2002 Aug; 54(2):171-7. PubMed ID: 12207637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update.
    Niemeijer MN; van den Berg ME; Eijgelsheim M; Rijnbeek PR; Stricker BH
    Drug Saf; 2015 Oct; 38(10):855-67. PubMed ID: 26108299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sibutramine-associated QT interval prolongation and cardiac arrest.
    Ernest D; Gershenzon A; Corallo CE; Nagappan R
    Ann Pharmacother; 2008 Oct; 42(10):1514-7. PubMed ID: 18728104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of drug-induced QT interval prolongation on drug discovery and development.
    Fermini B; Fossa AA
    Nat Rev Drug Discov; 2003 Jun; 2(6):439-47. PubMed ID: 12776219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecularly targeted oncology therapeutics and prolongation of the QT interval.
    Strevel EL; Ing DJ; Siu LL
    J Clin Oncol; 2007 Aug; 25(22):3362-71. PubMed ID: 17664484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acquired long QT syndrome].
    Zürcher JP; Schlaepfer J; Waeber G; Pasquier M
    Rev Med Suisse; 2013 Aug; 9(395):1538-42. PubMed ID: 24024425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease.
    Malek NM; Grosset KA; Stewart D; Macphee GJ; Grosset DG
    Parkinsonism Relat Disord; 2013 Jun; 19(6):586-9. PubMed ID: 23522959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Male/female differences in pharmacology: safety issues with QT-prolonging drugs.
    Anthony M
    J Womens Health (Larchmt); 2005; 14(1):47-52. PubMed ID: 15692277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of high-risk use of QT-prolonging medications.
    Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QTc interval prolongation by d-propoxyphene: what about other analgesics?
    Raffa RB; Burmeister JJ; Yuvasheva E; Pergolizzi JV
    Expert Opin Pharmacother; 2012 Jul; 13(10):1397-409. PubMed ID: 22568597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease inhibitor-associated QT interval prolongation.
    Hunt K; Hughes CA; Hills-Nieminen C
    Ann Pharmacother; 2011 Dec; 45(12):1544-50. PubMed ID: 22128044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.